

# ABL Biotechnologies Limited

Regd. Office: No.71, Nehru Nagar, Industrial Estate, 2nd Link Street, Kottivakkam, Chennai - 600 041.

Statement of Standalone/Consolidated Financial Results for the Quarter Ended 30.09.2014

(Rs. in Lakhs)

PART I

Particulars	3 months ended		Preceding 3 months ended		Corresponding 3 months ended		Year to Date figures for current		Year to Date figures for the		Previous Year ended	
	30.09.2014		31.08.2014		30.09.2013		30.09.2014		30.09.2013		31.03.2014	
	Unaudited standalone	Audited consolidated	Unaudited standalone	Audited consolidated	Unaudited standalone	Audited consolidated	Unaudited standalone	Audited consolidated	Unaudited standalone	Audited consolidated	Unaudited standalone	Audited consolidated
<b>Income from operations</b>												
(a) Net Sales/Income from Operations												
(b) Other Operating Income	0.16	0.16	0.16	0.16	0.16	0.16	0.32	0.32	0.32	0.32	0.65	0.65
<b>Total Income from operations (net)</b>	<b>0.16</b>	<b>0.16</b>	<b>0.16</b>	<b>0.16</b>	<b>0.16</b>	<b>0.16</b>	<b>0.32</b>	<b>0.32</b>	<b>0.32</b>	<b>0.32</b>	<b>0.65</b>	<b>0.65</b>
<b>Expenditure</b>												
(a) Increase/Decrease in Stock in trade and work in progress												
b) Consumption on Raw materials												
c) Product Development Cost												
d) conversion / other charges												
e) Purchase of traded goods												
f) Employee benefits expense	0.30	0.30	0.30	0.30			0.60	0.60				
g) Rent												
h) Travel & Conveyance Expenses	0.02	0.02					0.02	0.01				
i) Legal/Consultancy Expenses					0.04	0.04			0.11	0.11	0.42	0.42
j) Office Renovation												
k) bangalore shifting charges												
l) Communication Cost					0.01	0.01			0.01	0.01	0.01	0.01
m) Printing & Stationery	0.04	0.04					0.04	0.02				
n) Analysis, Testing & Dev exp												
o) RTA/BSE/CDS/MSDL Fees	0.49	0.49	0.70	0.70	0.10	0.10	1.19	1.19	0.90	0.90	1.07	1.07
p) Instrument maintenance												
q) Power, Fuel & Gas chges												
r) Consumables												
s) Audit Fees												
t) Bank Charges	0.07	0.07	0.01	0.01	0.02	0.02	0.08	0.08	0.02	0.02	0.34	0.34
u) Service Cost for labour												
v) Others												
w) Depreciation and amortisation expense	2.04	2.04	2.05	2.05	2.20	2.20	4.09	4.09	4.00	4.00	8.35	8.35
x) Preliminary expenses written off	1.23	1.23	1.23	1.23	1.23	1.23	2.46	2.46	2.46	2.46	4.92	4.92
y) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)												
<b>Total expenses</b>	<b>4.19</b>	<b>4.19</b>	<b>4.29</b>	<b>4.29</b>	<b>3.60</b>	<b>3.60</b>	<b>8.48</b>	<b>8.45</b>	<b>7.50</b>	<b>7.50</b>	<b>15.23</b>	<b>15.23</b>



Part II	ABL Biotechnologies Limited	Select information for the quarter ended 30/06/2014											
		3 months ended		Preceding 3 months ended		Corresponding 3 months ended in the previous year		Year to Date figures for current Period ended		Year to Date figures for the previous year ended		Previous Year ended	
		30.06.2014		31.06.2014		30.09.2013		30.09.2014		30.09.2013		31.03.2014	
Particulars		Unaudited standalone	Audited consolidated	Unaudited standalone	Audited consolidated	Unaudited standalone	Audited consolidated	Unaudited standalone	Audited consolidated	Unaudited standalone	Audited consolidated	Unaudited standalone	Audited consolidated
A	PUBLIC SHAREHOLDING												
1	- Number of shares	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000
	- Percentage of shareholding	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%
2	Promoters and promoter group Shareholding**												
	a) Pledged/Encumbered												
	- Number of shares												
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)												
	b) Non-encumbered												
	- Number of Shares	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%

Part II	INVESTOR COMPLAINTS	3 months ended on 30.09.2014
B	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil

Notes

- (1) Above results were taken on record by the Board of Directors at their meeting held on
- (2) Previous year/quarter figures have been regrouped where necessary.
- (3) ABL Research Pvt. Ltd. a 100% subsidiary of ABL Biotechnologies started activities in Research Projects effective April 2010 and incurred expenses of Rs. 94.22 lakhs in the DHA project as of September 30, 2014. These expenses, being in the nature of Project expenses, are accumulated and reported under Preliminary Operative Expenses as Non-current assets in the Balance sheet.

For ABL Biotechnologies Limited



Managing Director

Place : Chennai

Date : 11.11.2014

**ABL Biotechnologies Limited**

Regd. Office: No.71, Nehru Nagar, Industrial Estate, 2nd Link Street, Kottivakkam, Chennai - 600 041

Statement of Assets & Liabilities		ABL Biotechnologies Ltd				ABL Research	
		Sep. 30, 2014		Mar. 31, 2014		Sep. 30, 2014	Mar. 31, 2014
		Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
		Standalone	Consolidated	Standalone	Consolidated		
		Rs	Rs	Rs.	Rs.		
<b>A</b>	<b>EQUITY AND LIABILITIES</b>						
<b>1</b>	<b>Shareholders' funds</b>						
	(a) Share capital	8,20,00,000	8,20,00,000	8,20,00,000	8,20,00,000	1,00,000	1,00,000
	(b) Reserves and surplus	10,06,69,446	10,06,69,446	10,06,69,446	10,06,69,446		
	(c) Money received against share warrants						
	(d) Profit & Loss Account Debit Balance	-8,16,249	-8,16,249				
	<b>Sub-total - Shareholders' funds</b>	<b>18,18,53,197</b>	<b>18,18,53,197</b>	<b>18,26,69,446</b>	<b>18,26,69,446</b>	<b>1,00,000</b>	<b>1,00,000</b>
<b>2</b>	<b>Share application money pending allotment</b>						
<b>3</b>	<b>Minority Interest*</b>		10		10		
<b>4</b>	<b>Non-current liabilities</b>						
	(a) Long-term borrowings	12,99,02,917	13,79,84,789	12,93,95,907	13,67,19,279	80,81,872	73,23,372
	(b) Deferred tax liabilities (net)						
	(c) Other long-term liabilities						
	(d) Long-term provisions						
	<b>Sub-total - Non-current liabilities</b>	<b>12,99,02,917</b>	<b>13,79,84,789</b>	<b>12,93,95,907</b>	<b>13,67,19,279</b>	<b>80,81,872</b>	<b>73,23,372</b>
<b>5</b>	<b>Current liabilities</b>						
	(a) Short-term borrowings	4,31,48,244	4,31,48,244	4,31,48,244	4,31,48,244		
	(b) Trade payables ( Sundry Creditors)	4,60,96,149	4,69,93,152	4,64,96,149	4,77,64,461	8,97,003	12,68,312
	(c) Other current liabilities	4,76,29,931	4,80,40,050	4,75,35,903	4,81,61,889	4,10,119	6,25,986
	(d) Short-term provisions						
	<b>Sub-total - Current liabilities</b>	<b>13,68,74,324</b>	<b>13,81,81,446</b>	<b>13,71,80,296</b>	<b>13,90,74,594</b>	<b>13,07,122</b>	<b>18,94,298</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>44,86,30,438</b>	<b>45,80,19,442</b>	<b>44,92,45,649</b>	<b>45,84,63,329</b>	<b>94,88,994</b>	<b>93,17,670</b>

**ABL Biotechnologies Limited**

Regd. Office: No.71, Nehru Nagar, Industrial Estate, 2nd Link Street, Kottivakkam, Chennai - 600 041

	ABL Biotechnologies Ltd		ABL Research	
	Sep, 30, 2014	Mar, 31, 2014	Mar, 31 2014	Mar, 31 2013
	Audited	Audited	Audited	Audited
<b>ASSETS</b>	Standalone	Consolidated	Standalone	Consolidated
<b>1</b>				
<b>Non-currents assets</b>				
(a) Fixed assets	34,68,37,866	34,68,37,866	34,72,47,302	34,72,47,302
(b) Goodwill on consolidation*				
(c) Non-current investments	1,30,99,990	1,30,00,000	1,30,99,990	1,30,00,000
(d) Deferre tax assets (net)				
(e) Long-term loans and advances				
(f) Other non-current assets (Prel Exp)	20,43,411	1,14,65,601	22,89,411	1,13,02,153
<b>Sub-total - Non-current Assets</b>	<b>36,19,81,267</b>	<b>37,13,03,467</b>	<b>36,26,36,703</b>	<b>37,15,49,455</b>
<b>2</b>				
<b>Current assets</b>				
(a) Current investments		40,299		2,50,000
(b) Inventories				40,299
(c) Trade receivables	32,72,808	32,72,808	32,40,808	32,40,808
(d) Cash and cash equivalents	13,95,878	14,12,383	13,88,117	14,33,045
(e) Short-term loans and advances	8,19,80,485	8,19,90,485	8,19,80,021	8,19,90,021
(f) Other current assets				
<b>Sub-total - Current Assets</b>	<b>8,66,49,171</b>	<b>8,67,15,975</b>	<b>8,66,08,946</b>	<b>8,69,13,874</b>
<b>TOTAL - ASSETS</b>	<b>44,86,30,438</b>	<b>45,80,19,442</b>	<b>44,92,45,649</b>	<b>45,84,63,329</b>
			<b>94,88,994</b>	<b>93,17,670</b>